EDAP250117P7500
- 1.00
- 0.000.00%
EDAP TMS Newsroom
Express News | Edap Announces First Pancreatic Cancer Patient Treated With Proprietary Hifu Technology
EDAP Announces First Pancreatic Cancer Patient Treated With Proprietary HIFU Technology
Healthcare and Medical Simulation Market Size Expected to Reach USD 7.04 Bn by 2034
EDAP TMS Publishes HIFI Study Results In European Urology
Landmark HIFI Study Publication Demonstrates Positive Outcomes With Focal One Robotic HIFU Versus Surgery in the Management of Prostate Cancer
Express News | Senti Bio Appoints Fran Schulz to Board of Directors
European Equities Traded in the US as American Depositary Edge Higher in Wednesday Trading
EDAP to Participate in the Piper Sandler 36th Annual Healthcare Conference
Biden Proposes Medicare, Medicaid Coverage of Obesity Drugs
EDAP TMS SA Reports Technical Feasibility of Histotripsy Lesion Generation Using Focal One System
EDAP Announces Scientific Presentation Highlighting Feasibility of Focal One to Perform Non-thermal Histotripsy Energy Delivery at the 187th Acoustical Society of America Meeting
Express News | Edap Announces Scientific Presentation at 2024 Aagl Global Congress Comparing Focal One Hifu Versus Surgery for the Treatment of Deep Infiltrating Endometriosis
EDAP Announces Scientific Presentation at 2024 AAGL Global Congress Comparing Focal One HIFU Versus Surgery for the Treatment of Deep Infiltrating Endometriosis
EDAP TMS S.A. (EDAP) Q3 2024 Earnings Call Transcript Summary
Piper Sandler Maintains EDAP TMS(EDAP.US) With Buy Rating, Cuts Target Price to $5
H.C. Wainwright Maintains EDAP TMS(EDAP.US) With Buy Rating, Maintains Target Price $19
Edap TMS SA (EDAP) Q3 2024 Earnings Call Highlights: Record Revenue Growth Amidst Rising Expenses
European Equities Traded in the US as American Depositary Rise Thursday
EDAP TMS Sees Strong Growth and Advances in AI
EDAP TMS | 6-K: Report of foreign private issuer (related to financial reporting)